Savara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trial
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company, recently reported an increase in both research and development (R&D) and general administrative expenses for the fourth quarter and …
Savara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trial Read More